Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Type 2 diabetes is characterized by progressive beta-cell failure and loss of beta-cell mass.
• Obesity-associated hyperglycemia and elevated free fatty acids cause beta-cell glucolipotoxicity, with no current therapies targeting this in obese patients.
• Identifying novel therapeutic targets is crucial for preserving beta-cell function.

Purpose of the Study:

• To identify small molecules that protect pancreatic beta cells from glucolipotoxicity.
• To discover potential therapeutic agents for type 2 diabetes by screening for compounds that enhance beta-cell survival.

Main Methods:

• A high-throughput screen of 20,876 compounds was conducted using the INS-1E rat insulinoma cell line under glucolipotoxic conditions (elevated glucose and palmitate).
• Compounds demonstrating protective effects on INS-1E cell viability were further analyzed for known biological targets.
• Promising candidates were validated in dissociated human islets to assess their efficacy in reducing glucolipotoxicity-induced beta-cell death.

Main Results:

• 312 glucolipotoxicity-protective small molecules were identified, with 17 selected for further investigation based on known targets.
• 16 of these compounds were kinase inhibitors, including inhibitors of cyclin-dependent kinases (CDK), PI-3 kinase (PI3K), Janus kinase (JAK), and Rho-associated kinase 2 (ROCK2).
• Ten compounds (KD025, ETP-45658, BMS-536924, AT-9283, PF-03814735, torin-2, AZD5438, CP-640186, ETP-46464, GSK2126458) successfully reduced glucolipotoxicity-induced beta-cell death in human islets by decreasing caspase activation, mitochondrial depolarization, and calcium flux.

Conclusions:

• This study identified novel small molecules, primarily kinase inhibitors, that protect beta cells from glucolipotoxicity.
• These findings offer a promising foundation for developing new treatments to preserve beta-cell viability in type 2 diabetes patients.
• Targeting kinase pathways presents a viable strategy for combating beta-cell loss in the context of obesity and type 2 diabetes.